Groups target EU-Mercosur FTA to advance access to health in trade deals
AIDS activists, health activists and civil society organizations in Brazil and Argentina are pushing back against the negative effects of...
Gilead’s patent application on sofosbuvir rejected in Brazil
Rejected! That was the decision issued by Brazil’s National Institute of Industrial Property (INPI) over one of Gilead’s patent applications...
8 videos that explain the tension between HIV activists and Big Pharma
From Hollywood blockbusters, to investigative documentaries, to our own short, satirical animation, here are eight videos that show how the...
Fixing the broken patent system: From Marrakech and back again
Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical...
Storify: Pathways to Access #GSIPA2M
[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave
GSIPA2M: The Summit Highlights
Catch up on the activity from our inaugural Global Summit on Intellectual Property and Access to Medicines (15-17 January 2018)....
Argentina: Patent rejected on hepatitis C drug, sofosbuvir
A decision by the patent office in Argentina (INPI) to reject Gilead’s patent on key hepatitis C drug, sofosbuvir, is...
São Paulo protest exposes how Gilead’s actions block access to medicines around the world
In São Paulo, on 31 October 2017, activists from around the world held a protest at the headquarters of...
Brazil: 10 years of a Compulsory License on HIV drug Efavirenz
Symposium in Curitiba highlights the need for a collective fight to make medicines affordable. When governments are unreceptive, it is...
Victory: Gilead forced to withdraw Truvada® patent application in Argentina
Gilead prevented from obtaining an illegitimate monopoly at the expense of people’s health Activists in Argentina, including our partner...